BCAAs in Concussion 3.0

Part of paid clinical trials in Havertown, Pennsylvania.

Sponsor
Akiva Cohen
Study ID
NCT07670195
Phase
PHASE2
Status
Recruiting

Conditions

  • Concussion
  • Concussion (Diagnosis)
  • Concussion, Brain
  • MTBI - Mild Traumatic Brain Injury

Eligibility Criteria

Sex
ALL
Age
11 Years - 23 Years
Healthy Volunteers
Accepted

Interventions

  • BCAA — DRUG
    The three BCAAs will be combined together into a powder formulation.
  • Placebo — OTHER
    The placebo formulation will have similar taste, texture, consistency and appearance as the BCAA formulation.

Study Details

This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery.

Key Dates

First listed
Jun 26, 2026
Start date
Aug 5, 2026
Status verified
Aug 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Drug: Branched Chain Amino Acids
    The three BCAAs will be combined together into a powder formulation.
  • Placebo Comparator: Placebo
    The placebo formulation will have similar taste, texture, consistency and appearance as the BCAA formulation.

Primary Outcome Measure

Number of participants that have met have met criteria for recovery at 28 days post-injury, defined as return to baseline symptom levels along with feeling > 90% back to normal. [ Time Frame: 28 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Children's Hospital of PhiladelphiaHavertownPennsylvania19083
Daniel Corwin, MD
215-327-2306
Olivia Podolak
862-668-7645
Daniel Corwin, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Havertown, PA

Related Studies